Enforced expression of Bcl-x(S) induces differentiation and sensitizes chronic myelogenous leukemia-blast crisis K562 cells to 1-β-D- arabinofuranosylcytosine-mediated differentiation and apoptosis

Cell Growth and Differentiation

Volumn 7, Issue 12, 1996, Pages 1617-1623

  Ray, Swapan ^a   Bullock, Gloria ^a   Nuñez, Gabriel ^b   Tang, Caroline ^a   Ibrado, Ana Maria ^a   Huang, Yue ^a   Bhalla, Kapil ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; CYTARABINE; DNA FRAGMENT; HEMOGLOBIN; HERBIMYCIN A; HEXAMETHYLENEBISACETAMIDE; PROTEIN BCL 2; PROTEIN TYROSINE KINASE; RETINOBLASTOMA PROTEIN; RETINOIC ACID;

APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SENSITIVITY; ENZYME ACTIVITY; ETIOLOGY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIFFERENTIATION; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROID PROGENITOR CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID; NEOMYCIN; PLASMIDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSFECTION;

ARA;

EID: 0029852727     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Witte, O. N. Role of the BCR-ABL Oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation award lecture. Cancer Res., 53: 485-489, 1993.
2. Gale, P. R., Grosveld, G., Canaani, E., and Goldman, J. M. Chronic myelogenous leukemia: Biology and therapy. Leukemia (Baltimore), 7: 653-658, 1993.
3. Lozzio, C. B., and Lozzio, B. B. Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood, 45: 321-334, 1975.
4. Campbell, M. L., Lu, D., Guo, J. Q., and Arlinghaus, R. B. Inhibition of phosphorylation of p160 BCR within p210 BCR-ABL complexes during early stages of phorbol ester-induced differentiation of K562 cells. Cell Growth & Differ., 4: 581-588, 1993.
5. Leary, J. F., Ohlsson-Wilhelm, B. M., Giuliano, R., LaBella, S., Farley, B., and Rowley, P. T. Multipotent hematopoietic cell line K562: lineage-specific constitutive and inducible antigens. Leuk. Res., 11: 807-815, 1987.
6. Rosson, D., and O'Brien, T. G. Constitutive c-myb expression in K562 cells inhibits induced erythroid differentiation but not tetradecanoyl phorbol acetate-induced megakaryocytic differentiation. Mol. Cell. Biol., 15: 772-779, 1995.
7. Calabretta, B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: biological and therapeutic implications. Cancer Res., 51: 4505-4510, 1991.
8. Baker, S. J., Pawlita, M., Leutz, A., and Hoelzer, D. Essential role of c-myc in ara-C-induced differentiation of human erythroleukemia. Leukemia (Baltimore), 8: 1309-1319, 1994.
9. Feinstein, E., Gale, R. P., Reed, J., and Canaani, E. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene, 7: 1853-1857, 1992.
10. Yu, G., Smithgall, T. E., and Glazer, R. I. K562 leukemia cells transfected with the human c-fes gene acquired the ability to undergo myeloid differentiation. J. Biol. Chem., 264: 10276-10282, 1989.
11. Bolwell, B. J., Cassileth, P. A., and Gale, R. P. High dose cylarabine: a review. Leukemia (Baltimore), 2: 253-260, 1988.
12. Ray, S., Ponnathpur, V., Huang, Y., Tang, C., Mahoney, M. E., Ibrado, A. M., Bullock, G., and Bhalla, K. 1-β-D-Arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother. Pharmacol., 34: 365-371, 1994.
13. Bullock, G., Ray, S., Nawabi, A., Huang, Y., Ibrado, A. M., and Bhalla, K. Mechanisms and partial reversal of resistance to antileukemic drug-induced apoptosis in CML blast crisis K562 cells (Abstract). Blood, 84: 60, 1994.
14. 2/M transition after DMA damage: a mechanism of resistance to multiple anticancer agents. Blood, 86: 1148-1158, 1995.
15. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K. M., Green, D. R., and Cotter, T. G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83: 1179-1187, 1994.
16. Nuñez, G., and Clarke, M. F. The BCL-2 family of proteins: regulators of cell death and survival. Trends Cell. Biol., 4: 399-403, 1994.
17. Boise, L., Gonzalez-Garcia, M., Postema, C., Ding, L., Lindsten, T., Turka, L., Mao, X., Nuñez, G., and Thompson, C. BCL-x, a BCL-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell, 74: 597-608, 1993.
18. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DMA fragmentation. Cell Growth & Differ., 6: 363-370, 1995.
19. S sensitizes MCF-7 cells to chemotherapy-induced apoptosis. Cancer Res., 55: 2507-2510, 1995.
20. Benito, A., Grillot, D., Nuñez, G., and Fernandez-Luna, J. L. Regulation and function of BCL-2 during differentiation-induced cell death in HL-60 promyelocytic cells. Am. J. Pathol., 164: 481-490, 1995.
21. Luisi-DeLuca, C., Mitchell, T., Spriggs, D., and Kufe, D. W. Induction of terminal differentiation in human K562 erythroleukemia cells by arabinofuranosylcytosine. J. Clin. Invest., 74: 821-827, 1984.
22. Richon, V. M., Rifkind, R. A., and Marks, P. A. Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth & Differ., 3: 413-420, 1992.
23. Delgado, M. D., Lerga, A., Canelles, M., Gomez-Casares, M. T., and Leon, J. Differentiation regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene, 10: 1659-1665, 1995.
24. Okabe, M., Uehara, Y., Noshima, T., Itaya, T., Kunieda, Y., and Kurosawa, M. In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against Bcr/Abl oncoprotein in mice bearing Bcr-Abl-transfected cells. Leuk. Res., 18: 867-873, 1994.
25. Parks, J. R., Bernstein, I. D., and Hockenbery, D. M. Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood, 86: 868-876, 1995.
26. Sanchez-Garcia, I., and Grutz, G. Tumorigenic activity of the BCL-ABL oncogenes is mediated by BCL2. Proc. Natl. Acad. Sci. USA, 92: 5287-5291, 1995.
27. Robertson, K. A., Mueller, L., and Collins, S. J. Retinoic acid receptors in myeloid leukemia: characterization of receptors in retinoic acid-resistant K-562 cells. Blood, 77: 340-347, 1991.
28. Snyder, D. S., Wu, Y., Wang, J. L., Rossi, J. J., Swiderski, P., Kaplan, B. E., and Forman, S. J. Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line. Blood, 82: 600-605, 1993.
29. bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood, 82: 3524-3529, 1993.
30. bcr-abl transformation of murine myeloid cells. Blood, 82: 1838-1847, 1993.
31. Nichols, G. L., Raines, M. A., Vera, J. C., Lacomis, L., Tempst, P., and Golde, D. W. Identification of CRKL as the constitutively phosphorylated 39 kD tyrosine phosphoprotein in chronic myelogenous leukemia cells. Blood, 84: 2912-2918, 1994.
32. Reuther, G. W., Fu, H., Cripe, L. D., Collier, R. J., and Pendergast, A. M. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science (Washington, DC), 266: 129-133, 1994.
33. Skorski, T., Kanakaraj, P., Nieborowska-Skorska, M., Ratajczak, M. Z., Wen, S. C., Zon, G., Gewirtz, A. M., Perussia, B., and Calabretta, B. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood, 86: 726-736, 1995.
34. Zhang, W., Grasso, L., McClain, C. D., Gamel, A. M., Cha, Y., Travail, S., Deisseroth, A. B., and Mercer W. E. p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55: 668-674, 1995.
35. Arceci, R. J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood, 81: 2215-2222, 1993.
36. L in MRP or P-glycoprotein overexpressing multidrug resistant AML cells (Abstract). Blood, 86: 3043, 1995.
37. Krajewski, S., Krajewska, M., Shabaik, A., Wang, H. G., Irie, S., Fong, L., and Reed, J. C. Immunohistochemical analysis of in vivo patterns of BCL-x expression. Cancer Res., 54: 5501-5507, 1994.
38. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and Bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
39. Bhalla, K., Huang, Y., Tang, C., Self, S., Ray, S., Mahoney, M. E., Ponnathpur, V., Ibrado, A. M., Bullock, G., and Willingham, M. C. Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia (Baltimore), 8: 465-475, 1994.
40. Melloni, E., Pontremoli, S., Michetti, M., Sacco, O., Cakiroglu, A. G., Jackson, J. F., Rifkind, R. A., and Marks, P. A. Protein kinase C activity and hexamethylenebisacetamide-induced erythroleukemia cell differentiation. Proc. Natl. Acad. Sci. USA, 84: 5282-5286, 1987.